8-K: Lisata Therapeutics Terminates Certepetide China License

Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. have mutually terminated their exclusive license and collaboration agreement for certepetide in Greater China.

Summary

• Lisata Therapeutics, Inc. (formerly Cend Therapeutics, Inc.) and Qilu Pharmaceutical Co., Ltd. (Qilu) entered into a Mutual Termination Agreement on January 23, 2026.
• This agreement terminates the Exclusive License and Collaboration Agreement, originally dated February 11, 2021, and amended on April 26, 2021, and November 10, 2023.
• The original agreement granted Qilu a royalty-bearing exclusive license for the research, development, and commercialization of certepetide (formerly CEND-1) in the Greater China territory (Mainland China, Hong Kong, Macau, and Taiwan).
• Under the terminated agreement, Lisata was eligible to receive up to $200 million in development and commercial milestone payments and royalties ranging from 10% to 15% on licensed product sales.
• The termination is effective as of January 23, 2026, with certain accrued obligations and specified provisions surviving the termination.

Sentiment

Score: 3

Explanation: The termination of a licensing agreement that included up to $200 million in potential milestone payments and 10-15% royalties is a clear negative financial event, removing a significant potential revenue stream. While Lisata regains full rights to certepetide in Greater China, the immediate impact is a loss of a defined partnership and associated financial upside.

Negatives

• Loss of potential milestone payments up to $200 million from the terminated agreement.
• Loss of potential royalties ranging from 10% to 15% on certepetide sales in Greater China.
• Disruption to the established development and commercialization strategy for certepetide in the Greater China territory.

Risks

• Loss of significant potential future revenue streams from milestone payments and royalties.
• Uncertainty regarding the future development and commercialization path for certepetide in Greater China.
• Potential need for Lisata to invest additional resources to pursue development and commercialization in the region independently or seek a new partner.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding the future development or commercialization strategy for certepetide in Greater China following the termination.

Industry Context

The termination of a significant regional licensing agreement for a drug candidate like certepetide can reflect various factors, including strategic shifts by either party, changes in market outlook, or challenges in development. It highlights the inherent risks and evolving nature of pharmaceutical partnerships, particularly in competitive markets like Greater China.

Stakeholder Impact

• Shareholders: Potential negative impact due to the loss of anticipated milestone payments and royalties, which could affect future revenue projections and stock valuation.
• Customers/Patients: Potential impact on the timeline or availability of certepetide in Greater China, depending on Lisata's future strategy for the region.

Key Dates

Recommendation

The termination of a significant licensing agreement, while removing a substantial potential revenue stream (up to $200 million in milestones and 10-15% royalties), also returns full rights to certepetide in the Greater China territory to Lisata. This creates uncertainty but also potential for a new, potentially more favorable, partnership or direct development. Given the immediate loss of defined future payments but the retention of asset value, a 'hold' recommendation is appropriate as investors await clarity on Lisata's revised strategy for this key asset and region.

Keywords

Lisata Therapeutics, Qilu Pharmaceutical, certepetide, CEND-1, license agreement, termination, biotechnology, pharmaceuticals, Greater China, milestone payments, royalties, drug development